4,189 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Purchased by Bleakley Financial Group LLC

Bleakley Financial Group LLC acquired a new position in shares of 10x Genomics, Inc. (NASDAQ:TXG) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 4,189 shares of the company’s stock, valued at approximately $234,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in TXG. Indiana Trust & Investment Management CO purchased a new stake in 10x Genomics during the 3rd quarter worth about $29,000. Atlas Capital Advisors LLC increased its position in 10x Genomics by 41.7% during the 2nd quarter. Atlas Capital Advisors LLC now owns 935 shares of the company’s stock worth $42,000 after purchasing an additional 275 shares in the last quarter. UMB Bank n.a. increased its position in 10x Genomics by 51.6% during the 4th quarter. UMB Bank n.a. now owns 782 shares of the company’s stock worth $44,000 after purchasing an additional 266 shares in the last quarter. Comerica Bank purchased a new stake in 10x Genomics during the 3rd quarter worth about $64,000. Finally, PNC Financial Services Group Inc. grew its holdings in 10x Genomics by 17.9% in the 2nd quarter. PNC Financial Services Group Inc. now owns 1,299 shares of the company’s stock valued at $73,000 after buying an additional 197 shares during the period. Hedge funds and other institutional investors own 84.68% of the company’s stock.

10x Genomics Price Performance

NASDAQ TXG opened at $32.86 on Tuesday. The firm has a market capitalization of $3.92 billion, a P/E ratio of -15.14 and a beta of 1.90. 10x Genomics, Inc. has a 1-year low of $32.68 and a 1-year high of $63.57. The business’s 50-day simple moving average is $41.22 and its 200-day simple moving average is $43.28.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Thursday, February 15th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.05). The firm had revenue of $183.98 million during the quarter, compared to analyst estimates of $182.73 million. 10x Genomics had a negative net margin of 41.17% and a negative return on equity of 28.82%. The business’s revenue for the quarter was up 17.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.15) earnings per share. On average, equities research analysts expect that 10x Genomics, Inc. will post -1.47 EPS for the current fiscal year.

Insider Activity

In related news, insider Benjamin J. Hindson sold 2,613 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total transaction of $121,086.42. Following the transaction, the insider now directly owns 283,059 shares of the company’s stock, valued at approximately $13,116,954.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Benjamin J. Hindson sold 2,613 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total transaction of $121,086.42. Following the transaction, the insider now directly owns 283,059 shares of the company’s stock, valued at approximately $13,116,954.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Serge Saxonov sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $49.53, for a total value of $49,530.00. Following the transaction, the chief executive officer now directly owns 855,381 shares in the company, valued at $42,367,020.93. The disclosure for this sale can be found here. Insiders have sold 12,959 shares of company stock valued at $592,806 in the last three months. Corporate insiders own 10.65% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on TXG. Barclays lowered their price target on 10x Genomics from $55.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday, April 10th. Stifel Nicolaus lowered their price target on 10x Genomics from $68.00 to $63.00 and set a “buy” rating for the company in a report on Friday, February 16th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $60.88.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.